Aug 26, 2019 / 12:00PM GMT
Operator
My name is Laura, and I will be your conference facilitator today for Amgen's conference call on the acquisition of Otezla. (Operator Instructions)
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
Arvind Sood - Amgen Inc. - VP of IR
Okay, Laura, thank you. Good morning, everybody, and thanks for joining us on short notice.
Our announced acquisition of Otezla this morning is an important step in adding to our leadership
in the inflammation space. To address this in greater detail, I'm joined with -- joined by several members of our leadership team this morning.
And just a reminder that some of the statements we make today will be forward-looking statements and our SEC filings identify factors that could cause our actual results to differ materially.
So with that, I would like to turn the call over to Bob Bradway, our CEO. Bob?
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Okay, Arvind. Thank
Amgen Inc to Acquire Worldwide Rights to Otezla® from Celgene Corp - Conference Call Transcript
Aug 26, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers